Jacobi Capital Management LLC bought a new stake in OptimizeRx Co. (NASDAQ:OPRX) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 700 shares of the company’s stock, valued at approximately $34,000.
Other hedge funds also recently bought and sold shares of the company. Dorsey Wright & Associates lifted its holdings in shares of OptimizeRx by 134.2% in the first quarter. Dorsey Wright & Associates now owns 1,707 shares of the company’s stock valued at $83,000 after purchasing an additional 978 shares in the last quarter. Citigroup Inc. lifted its holdings in shares of OptimizeRx by 301.4% in the fourth quarter. Citigroup Inc. now owns 2,806 shares of the company’s stock valued at $87,000 after purchasing an additional 2,107 shares in the last quarter. Precision Wealth Strategies LLC bought a new position in shares of OptimizeRx in the first quarter valued at approximately $233,000. Victory Capital Management Inc. bought a new stake in OptimizeRx during the first quarter worth $283,000. Finally, JPMorgan Chase & Co. lifted its holdings in OptimizeRx by 21.1% during the fourth quarter. JPMorgan Chase & Co. now owns 6,578 shares of the company’s stock worth $205,000 after acquiring an additional 1,147 shares during the period. Institutional investors own 64.72% of the company’s stock.
In other news, President Miriam J. Paramore sold 1,667 shares of OptimizeRx stock in a transaction on Friday, June 4th. The stock was sold at an average price of $51.30, for a total value of $85,517.10. Following the completion of the transaction, the president now directly owns 7,412 shares in the company, valued at $380,235.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO William J. Febbo sold 80,000 shares of OptimizeRx stock in a transaction on Thursday, March 25th. The shares were sold at an average price of $46.10, for a total value of $3,688,000.00. Following the completion of the transaction, the chief executive officer now owns 273,278 shares of the company’s stock, valued at $12,598,115.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 138,909 shares of company stock valued at $6,411,280. 8.10% of the stock is owned by company insiders.
A number of brokerages recently commented on OPRX. Roth Capital lifted their price target on OptimizeRx from $70.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, February 25th. B. Riley lifted their price target on OptimizeRx from $75.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, May 7th. Royal Bank of Canada assumed coverage on OptimizeRx in a report on Monday, April 12th. They set an “outperform” rating and a $65.00 price target on the stock. Finally, Zacks Investment Research raised OptimizeRx from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research report on Saturday, May 22nd. Five analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $67.80.
OptimizeRx Corporation operates as a digital health company that provides communications solutions for life science companies, physicians, and patients. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, therapeutic support messages, and unbranded messages.
See Also: Quiet Period Expirations
Want to see what other hedge funds are holding OPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Co. (NASDAQ:OPRX).
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.